Key result
Empagliflozin provides consistent CV and renal benefits in HFrEF regardless of ischemic or nonischemic cause.
RCT
Answers are grounded in this paper and cite their sources.
May support empagliflozin across HFrEF etiologies; hypothesis-generating for etiology-specific effects.
interaction=0.15). The benefit of empagliflozin on HF hospitalization, the renal composite end point, estimated glomerular filtration slope changes, and health status scores were also consistent in both groups without treatment by cause modification. Conclusions Empagliflozin offers cardiovascular and renal benefits in patients with heart failure with reduced ejection fraction regardless of the cause of HF. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03057977.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2022) conducted an RCT in Heart failure with reduced ejection fraction. Empagliflozin was evaluated. Empagliflozin provided consistent cardiovascular and renal benefits in patients with heart failure with reduced ejection fraction regardless of ischemic or nonischemic cause.
Synapse has enriched 10 related papers. Consider them for comparative context: